Xiaozhong Qian

Xiaozhong (Max) Qian holds extensive experience in the field of oncology and translational medicine, currently serving as Executive Director and Group Leader for Oncology Translational Sciences Late ADC at Daiichi Sankyo, Inc. Previous roles include Senior Director in Oncology Translational Sciences at Bristol-Myers Squibb, Clinical Biomarker Lead in Translational Medicine focusing on Immuno-Oncology, and Associate Director of Translational Development and Diagnosis at Celgene. Xiaozhong's career also features significant contributions as Senior Principal Scientist at Forest Laboratories (Abbvie), Project Leader at Celldex (Curagen), and Scientist at Regeneron Pharmaceuticals. Educational qualifications include studies at The Johns Hopkins University School of Medicine and The Chinese Academy of Sciences.